Interstitial Cystitis Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies -Mylan Pharmaceuticals, UCB Pharmaceuticals, Astellas Pharmaceuticals

(Las Vegas, Nevada, United States) "Interstitial Cystitis Market Insights, Epidemiology, and Market Forecast-2030" report deliver an in-depth understanding of the Interstitial Cystitis, historical and forecasted epidemiology as well as the Interstitial Cystitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Download Sample Report to know more @https://www.delveinsight.com/sample-request/interstitial-cystitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Interstitial Cystitis Overview
Interstitial Cystitis, also called Painful Bladder Syndrome, is a chronic condition causing bladder pressure, bladder pain, and sometimes pelvic pain. The pain ranges from mild discomfort to severe levels. The bladder is a hollow, muscular organ that stores urine, which expands until it is full and then gives signals to the brain that it is time to urinate, communicating through the pelvic nerves; this creates the urge to urinate for most people. With Interstitial Cystitis, these signals get mixed up, and then patients feel the need to urinate more often and with smaller volumes of urine than most people. This condition most often affects women and can have a long-lasting impact on their quality of life.

Click here to learn more about the Interstitial Cystitis Market Landscape @https://www.delveinsight.com/report-store/interstitial-cystitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Key Highlights from Interstitial Cystitis Market Report
The Interstitial Cystitis Association has demarcated that 3-8 million women in the United States may have IC, which is about 3-6% of all women in the US. On the other hand, 1-4 million men have IC as well. However, this number is likely lower than the true rate because IC in men may often be mistaken for another disorder, such as chronic prostatitis/chronic pelvic pain syndrome. The number of men often remains underdiagnosed or underestimated.
The total diagnosed prevalent population of IC in the seven major markets was found to be 2,597,669 in 2021, wherein the diagnosed prevalent population of IC patients in the United States was found to be 1,682,734 in 2021.

Interstitial CystitisTreatment Market
Since the etiology and pathogenesis of IC are not well understood and there is no curative treatment, the goal of management is to provide relief of symptoms to improve the quality of life of the patients. However, still, bladder pain syndrome can be treated using a step-wise approach depending upon the identified risk of adverse effects and the invasiveness of the treatment options. The therapeutic options used to treat IC include over-the-counter medicines (Aspirin, Acetaminophen, NSAIDs, etc.), non-narcotic pain medicines (Pyridium, Topical Medicines, Lidocaine Patch, etc.), narcotic pain medicines (Codeine, Oxycodone, Tapentadol, etc.)
Other interventions include the use of physical therapy, antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), Bladder Installations, Immunosuppressants, etc.
Till date, there are only two approved therapies to treat IC such as oral Elmiron (Pentosan polysulfate sodium) and intravesical Dimethyl Sulfoxide (DMSO).

Learn more about the treatment market for Interstitial Cystitis @ https://www.delveinsight.com/report-store/interstitial-cystitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

The Report Covers the Interstitial Cystitis Epidemiology Segmented by:
Interstitial Cystitis Prevalent cases
Interstitial Cystitis Incident Cases
Interstitial Cystitis treatment cases
Interstitial Cystitis Diagnosed cases
Interstitial Cystitis Dug Profile and Companies Covered
Elmiron: Janssen Pharmaceutical
RIMSO-50: Mylan Pharmaceutical
KRP-116D: Kyorin Pharmaceutical
Certolizumab pegol (Cimzia): UCB Pharma
LP-08: Lipella Pharmaceuticals
LP-08, investigated by Lipella Phar
GRT6010: Grünenthal
ASP6294: Astellas Pharma
SI-722: Seikagaku Corporation
And many others.

Learn more about the Key Companies and Emerging Therapies in the Interstitial Cystitis Market @https://www.delveinsight.com/report-store/interstitial-cystitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Table of Contents
Key Insights
Interstitial Cystitis Introduction
Executive Summary of Interstitial Cystitis
Disease Background and Overview
Interstitial Cystitis Epidemiology and patient population
Interstitial Cystitis Emerging Therapies
Interstitial Cystitis Market Outlook
Interstitial Cystitis Market Access and Reimbursement of Therapies
Interstitial Cystitis Market Drivers
Interstitial Cystitis Market Barriers
Appendix
Interstitial Cystitis Report Methodology
DelveInsight Capabilities
Disclaimer

Learn about the detailed offerings of the Interstitial Cystitis Market Outlook report @ https://www.delveinsight.com/report-store/interstitial-cystitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Related Reports
Interstitial Cystitis Epidemiology Forecast
https://www.delveinsight.com/report-store/interstitial-cystitis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Interstitial Cystitis Pipeline Forecast
https://www.delveinsight.com/report-store/interstitial-cystitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
DelveInsight Business Research LLP
Adya Kaul
info@delveinsight.com
https://www.delveinsight.com

DelveInsight Business Research LLP
Adya Kaul
info@delveinsight.com
https://www.delveinsight.com

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.